Delpharm Sustainability Profile
Delpharm, a leading contract development and manufacturing organisation (CDMO), is headquartered in France and operates extensively across Europe and beyond. Founded in 1998, Delpharm has established itself as a key player in the pharmaceutical industry, specialising in the production of solid forms, liquids, and semi-solids. The company is renowned for its commitment to quality and innovation, offering tailored solutions that meet the diverse needs of its clients. Delpharm's state-of-the-art facilities and adherence to stringent regulatory standards have positioned it as a trusted partner for pharmaceutical companies worldwide. With a focus on sustainability and efficiency, Delpharm continues to achieve significant milestones, reinforcing its reputation as a reliable provider in the competitive landscape of pharmaceutical manufacturing.
DitchCarbon Score
How does Delpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Delpharm's score of 56 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Delpharm's reported carbon emissions
In 2024, Delpharm reported total carbon emissions of approximately 37662000 kg CO2e for Scope 1 and about 4291000 kg CO2e for Scope 2. The company’s Scope 3 emissions were significantly higher, totalling around 680660000 kg CO2e. This data reflects Delpharm's commitment to transparency in its carbon footprint across all scopes of emissions. Delpharm has set ambitious reduction targets, aiming for a 42% decrease in absolute emissions related to Scope 1 and Scope 2 by early 2025. These targets have been submitted to the Science Based Targets initiative (SBTi), aligning with global efforts to limit warming to 1.5°C. The baseline for this reduction is set from 2022, demonstrating Delpharm's proactive approach to climate action. In 2023, the company reported slightly higher emissions, with Scope 1 at approximately 39887000 kg CO2e and Scope 2 at about 4668000 kg CO2e, while Scope 3 emissions were around 695597000 kg CO2e. This indicates a need for ongoing efforts to meet their reduction goals. Delpharm's commitment to sustainability is further underscored by its participation in the SBTi, which certifies that their targets are in line with scientific recommendations for climate stability. The company is actively working towards these goals, reflecting its dedication to reducing its environmental impact within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 39,887,000 | 00,000,000 |
| Scope 2 | 16,182,000 | 00,000,000 |
| Scope 3 | 695,597,000 | 000,000,000 |
How Carbon Intensive is Delpharm's Industry?
How Carbon Intensive is Delpharm's Location?
Delpharm's Scope 3 Categories Breakdown
Delpharm's Scope 3 emissions, which decreased by 2% last year and decreased by approximately 2% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 88% of Scope 3 emissions.
Top Scope 3 Categories
Delpharm's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Delpharm has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim Pharmaceuticals, Inc.
Frequently Asked Questions
Common questions about Delpharm's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.